Jan 08, 2024 / 10:15PM GMT
Christopher Thomas Schott - JPMorgan Chase & Co, Research Division - Senior Analyst
Good afternoon, everybody. I'm Chris Schott from JPMorgan, and it's my pleasure to be introducing Regeneron today. From the company, we're going to have presentations from Co-Founders and Co-Chairs, President and CEO, Len Schleifer; as well as President and CSO, George Yancopoulos.
2023 was obviously a very successful year for the company, significant progress across both the core drivers as well as the pipeline and looking forward to the update from the team today on the business for '24 and beyond. So with that, turn it over to Len.
Leonard S. Schleifer - Regeneron Pharmaceuticals, Inc. - Co-Founder, President, CEO & Co-Chairman
Thank you, Chris. It's great to be here. Let me start with a very important piece of business. I think as everybody knows and we announced several months ago, our spectacular CFO, Bob Landry, will be moving on to greener pastures. So Bob, thank you very much for leaving us in such a great shape, and we welcome Chris Fenimore, who will
Regeneron Pharmaceuticals Inc at JPMorgan Healthcare Conference Transcript
Jan 09, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers